EYLEA has also been approved by the European Commission and in Japan for the treatment of visual impairment due to Macular Edema secondary to CRVO. Regeneron maintains exclusive rights to EYLEA in the United States. About Regeneron Pharmaceuticals Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.